Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MBX Biosciences, Inc.

Get SEC filing alerts via email and in your feed for MBX Biosciences, Inc.

MBX

MBX Biosciences, Inc.

About MBX Biosciences, Inc.

MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform designs long-acting, highly selective peptides with optimized pharmacokinetics for conditions like hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company focuses on innovative, convenient treatments that improve efficacy, tolerability, and patient compliance through advanced chemical modifications and programmable prodrug technologies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MBX Biosciences, Inc.

1
1
MBX Biosciences, Inc. MBX Biosciences Reports $23.5 Million Net Loss in Q1 2026, Plans Phase 3 Trial for Canvuparatide

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
MBX Biosciences, Inc. MBX Biosciences Reports $87M Net Loss and Business Update in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MBX Biosciences, Inc. MBX Biosciences Reports $21.6 Million Net Loss in Latest Quarter, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MBX Biosciences, Inc. MBX Biosciences Reports $19.4 Million Net Loss in Q2 2025, Increases Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MBX Biosciences, Inc. MBX Biosciences Reports $23.9 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments